Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)

Part of paid clinical trials in Santa Monica, California.

Sponsor
Merck Sharp & Dohme LLC
Study ID
NCT06596694
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Gastrointestinal Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Patritumab deruxtecan — BIOLOGICAL
    Administered via intravenous (IV) infusion

Study Details

Researchers want to learn if patritumab deruxtecan (MK-1022) can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are advanced (the cancer has spread to other parts of the body). The goals of this study are to learn: * About the safety and how well people tolerate of patritumab deruxtecan * How many people have the cancer respond (get smaller or go away) to treatment

Key Dates

Start date
Nov 3, 2024
Status verified
May 2026
Primary completion
Dec 7, 2028
Completion
Dec 7, 2028

Study Design

Enrollment
180 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Patritumab deruxtecan
    Participants receive patritumab deruxtecan intravenous (IV) infusion on Day 1 of each 21-day cycle (every 3 weeks) until disease progression, intolerable toxicity, or investigator decision.

Primary Outcome Measure

Number of Participants Experiencing Dose-Limiting Toxicity (DLT) (Dose-Escalation Phase) [ Time Frame: Up to 21 days ]

Central Contacts

Locations (13)

FacilityCityStateZIPSite coordinators
UCLA Hematology Oncology Santa Monica ( Site 1205)Santa MonicaCalifornia90404
Study Coordinator
310-633-8400
University of Colorado Cancer Center ( Site 1200)AuroraColorado80045
Study Coordinator
720-848-0300
Sibley Memorial Hospital ( Site 1208)Washington D.C.District of Columbia20016
Study Coordinator
202-660-6500
University of Florida ( Site 1202)GainesvilleFlorida32610
Study Coordinator
352-273-5045
Mount Sinai Medical Center Comprehensive Cancer Center ( Site 1213)Miami BeachFlorida33140
Study Coordinator
305-674-2625
Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 1203)MariettaGeorgia30060-
University of Chicago Medical Center ( Site 1204)ChicagoIllinois60637
Study Coordinator
773-702-1220
Renown Regional Medical Center ( Site 1221)RenoNevada89502
Study Coordinator
775-982-5786
NYU Langone Hospital - Long Island ( Site 1230)MineolaNew York11501
Study Coordinator
516-663-8358
Perlmutter NYU Cancer Center ( Site 1212)New YorkNew York10016
Study Coordinator
917-743-3520
Scott & White Medical Center-Temple ( Site 1224)TempleTexas76508
Study Coordinator
254-760-0867
Oncology and Hematology Associates of Southwest Virginia (BRCC) ( Site 1207)RoanokeVirginia24014
Study Coordinator
540-982-0237
University of Wisconsin ( Site 1210)MadisonWisconsin53792
Study Coordinator
800-622-8922

Find similar trials in Santa Monica, CA

By research site
UCLA Hematology Oncology Santa Monica· Santa Monica, CAUniversity of Colorado Cancer Center· Aurora, COSibley Memorial Hospital· Washington D.C., DCUniversity of Florida· Gainesville, FLMount Sinai Medical Center Comprehensive Cancer Center· Miami Beach, FLNorthwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research· Marietta, GA

Related Studies